This article is more than 5 years old. Information may no longer be current.

NSAIDs associated with reduced colorectal cancer mortality

Issue: November 25, 2011

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

AACR Frontiers in Cancer Prevention Research

Postmenopausal women who used NSAIDs for 10 years or more had a lower risk for colorectal cancer death, according to new findings from the Women's Health Initiative study.

Study results showed that prolonged NSAID use before diagnosis was significantly associated with reduced colorectal cancer mortality (HR=0.70; 95% CI, 0.52-0.93).

"The [Women's Health Initiative] study population represents a large and well-characterized cohort of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use," Anna E. Coghill, MPH, a doctoral student in epidemiology at the University of Washington and Fred Hutchinson Cancer Research Center, said in a press release. "Our results suggest that [NSAID] use is associated with lower colorectal cancer mortality among postmenopausal women who use these medications more consistently and for longer periods of time."

Coghill presented the results at the 10th AACR International Conference on Frontiers in Cancer Prevention Research.

There were 160,143 women who participated in the study, none of whom had a history of colorectal cancer at baseline. Researchers found 2,119 colorectal cancer diagnoses and 492 disease-specific deaths.

Among women who lived to 3 years after study enrollment (98%), those who reported use of NSAIDs both at baseline and at year 3 had a 30% reduction in colorectal cancer mortality (HR=0.72; 95% CI, 0.54-0.95) compared with women who did not report use at both time points. Researchers determined that NSAID use at baseline - including aspirin, ibuprofen and prescription medications - was not associated with colorectal cancer mortality (HR=0.93; 95% CI, 0.76-1.14).

For more information:

• Coghill AE. #A69. Presented at: 10th AACR International Conference on Frontiers in Cancer Prevention Research; Oct. 22-25, 2011; Boston.

Follow HemOncToday.com on Twitter.